Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT07193511 is registered in ClinicalTrials.gov with Avenzo Therapeutics, Inc. as lead sponsor.

NCT NCT07193511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07193511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Lead sponsor
Avenzo Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 2, 2025
Completion date
September 30, 2030
Enrollment
355 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced, metastatic solid tumors, solid tumor cancer, urothelial cancer